Search results for "Neoplasms"

showing 10 items of 7988 documents

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

2018

Current treatment options for advanced and recurrent head and neck squamous cell carcinoma (HNSCC) enclose radiation and chemo-radiation approaches with or without surgery. While platinum-based chemotherapy regimens currently represent the gold standard in terms of efficacy and are given in the vast majority of cases, new chemotherapy regimens, namely immunotherapy are emerging. However, the response rates and therapy resistance mechanisms for either chemo regimen are hard to predict and remain insufficiently understood. Broad variations of chemo and radiation resistance mechanisms are known to date. This study describes the development of a standardized, high-throughput in vitro assay to a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGeneral Chemical Engineeringmedicine.medical_treatmentCell Culture TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences3D cell culture0302 clinical medicineInternal medicinemedicineCarcinomaHumansPrecision MedicineChemotherapyGeneral Immunology and MicrobiologySquamous Cell Carcinoma of Head and Neckbusiness.industryGeneral NeuroscienceHead and neck cancerImmunotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good healthRegimen030104 developmental biologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellPersonalized medicinebusinessJournal of Visualized Experiments
researchProduct

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.

2020

PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyHematologyendocrine system diseasesbusiness.industrydigestive system diseases3. Good healthBRAF V600E03 medical and health sciencesenzymes and coenzymes (carbohydrates)030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)Original Reportsmedicinebusinessskin and connective tissue diseasesneoplasmsChemoradiotherapyJCO precision oncology
researchProduct

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

2019

A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has ‘aggressive disease’, as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung NeoplasmsTime FactorsBevacizumabmedicine.medical_treatmentDocetaxelAntibodies Monoclonal HumanizedDisease-Free SurvivalRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerLungChemotherapybusiness.industryPatient SelectionAntibodies MonoclonalGeneral Medicinemedicine.diseaserespiratory tract diseasesBevacizumab030104 developmental biologyOncologychemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaNintedanibNivolumabbusinessmedicine.drugFuture oncology (London, England)
researchProduct

Trifluridine/tipiracil : an emerging strategy for the management of gastrointestinal cancers

2018

Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article reviews the clinical value of trifluridine/tipiracil as a monotherapy, including recent trials in GI cancers, and the potential benefit of combining it with other agents in patients with GI cancers, including the preclinical rationale for combination therapy and recently completed and ongoing clinical trials. Data gathered so far suggest that trifluridine/tipiracil has t…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesPyrrolidinesOrganoplatinum CompoundsCombination therapyColorectal cancerTrifluridineDocetaxelIrinotecanTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGastrointestinal cancerContinuum of careUracilGastrointestinal NeoplasmsTipiracilClinical Trials as Topicbusiness.industryGeneral Medicinemedicine.diseaseBevacizumabOxaliplatinClinical trialDrug Combinations030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisColonic NeoplasmsQuality of LifeClinical valueCamptothecinTaxoidsFluorouracilImmunotherapyHuman medicinebusinessThyminemedicine.drugFuture oncology
researchProduct

Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer.

2018

Aim: Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods: The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabColorectal cancermedicine.medical_treatmentSABR volatility modelRadiosurgery03 medical and health sciences0302 clinical medicineInternal medicineAblative casemedicineHumansAgedRetrospective StudiesLungbusiness.industryGeneral MedicineOxygenationMiddle Agedmedicine.diseaseCombined Modality TherapyRadiation therapyBevacizumab030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic Neoplasmsbusinessmedicine.drugTumori
researchProduct

Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis

2018

Background: Recent studies evaluated the diagnostic accuracy of circulating tumor DNA (ctDNA) analysis in the detection of epidermal growth factor receptor (EGFR) mutations from plasma of NSCLC patients, overall showing a high concordance as compared to standard tissue genotyping. However it is less clear if the location of metastatic site may influence the ability to identify EGFR mutations. Objective: This pooled analysis aims to evaluate the association between the metastatic site location and the sensitivity of ctDNA analysis in detecting EGFR mutations in NSCLC patients. Methods: Data from all published studies, evaluating the sensitivity of plasma-based EGFRmutation testing, stratifi…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsGenotypeSettore MED/06 - Oncologia MedicaConcordanceEGFRintrathoracicReal-Time Polymerase Chain ReactionNSCLCMetastasisCirculating Tumor DNACohort Studies03 medical and health sciencesT790M0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansmetastasisLiquid biopsyNeoplasm MetastasisLung cancerGenotypingextrathoracicEGFR; NSCLC; ctDNA; extrathoracic; intrathoracic; liquid biopsy; metastasisPharmacologyChi-Square Distributionliquid biopsybusiness.industryOdds ratioctDNAmedicine.diseaseConfidence intervalData AccuracyErbB Receptors030104 developmental biologyOncology030220 oncology & carcinogenesisMutationHuman medicinebusiness
researchProduct

Contribution of MUTYH variants to male breast cancer risk: results from a multicenter study in Italy

2018

Inherited mutations in BRCA1, and, mainly, BRCA2 genes are associated with increased risk of male breast cancer (MBC). Mutations in PALB2 and CHEK2 genes may also increase MBC risk. Overall, these genes are functionally linked to DNA repair pathways, highlighting the central role of genome maintenance in MBC genetic predisposition. MUTYH is a DNA repair gene whose biallelic germline variants cause MUTYH-associated polyposis (MAP) syndrome. Monoallelic MUTYH variants have been reported in families with both colorectal and breast cancer and there is some evidence on increased breast cancer risk in women with monoallelic variants. In this study, we aimed to investigate whether MUTYH germline v…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMUTYHBRCA1/2; MUTYH; MUTYH-associated polyposis (MAP) syndrome; NGS; breast cancer risk; genetic susceptibility; male breast cancerPALB2male breast cancerlcsh:RC254-28203 medical and health sciencesbreast cancer risk0302 clinical medicineBreast cancerMUTYHBRCA1/2Internal medicinemedicineGenetic predispositionskin and connective tissue diseasesCHEK2MUTYH-associated polyposis (MAP) syndromeOriginal Researchbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPenetrancemale breast cancer; genetic susceptibility; BRCA1/2; MUTYH; NGS; MUTYH-associated polyposis (MAP) syndrome; breast cancer risk030104 developmental biologyOncology030220 oncology & carcinogenesisMale breast cancerNGSbusinessgenetic susceptibility
researchProduct

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

2019

Background Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Methods We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total participants during follow-up in ALT+ versus ALT- pati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisMesenchymalSurvivalALTlcsh:RC254-282digestive systemRisk Assessmentnot known03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicineGeneticsmedicineHumansClinical significanceALT; ATR; ATRX; Mesenchymal; Prognosis; Sarcoma; SurvivalProportional Hazards Modelsbusiness.industryHazard ratioSoft tissueTelomere HomeostasisSarcomaMiddle AgedTelomeremedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisSurvival Analysisdigestive system diseases3. Good health030104 developmental biologyATRATRXOncology030220 oncology & carcinogenesisRelative riskMeta-analysisSarcomabusinessResearch ArticleBMC Cancer
researchProduct

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

2021

BackgroundThe prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.MethodsWe performed in silico analyses in more than 2800 early breast cancer transcriptomes with corresponding clinical annotations. We first developed a new gene expression deconvolution algorithm that accurately estimates the quantity of immune cell populations (tumor immune contexture,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMyeloid2435In silicoImmunologyCellbiostatisticsBreast NeoplasmsTranscriptome03 medical and health sciences0302 clinical medicineBreast cancerImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorImmunology and Allergytumor microenvironmentHumans1506Stage (cooking)RC254-282Neoplasm StagingPharmacologyClinical/Translational Cancer ImmunotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisSurvival AnalysisGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesistumor biomarkersMolecular MedicineFemalebusinessAlgorithmsUnsupervised Machine LearningJournal for Immunotherapy of Cancer
researchProduct

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

2018

© 2018 by the authors.

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNPM1PTK2acute myeloid leukemialcsh:RC254-282Article03 medical and health sciences0302 clinical medicinePTK2BLYNInternal medicinehemic and lymphatic diseasesmedicineLYNprognostic factorPrognostic factorintermediate-riskPTK2BAcute myeloid leukemiaPTK2business.industryMyeloid leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCohortIntermediate-riskbusinessTyrosine kinaseProto-oncogene tyrosine-protein kinase SrcCancers
researchProduct